Lyrica Pregabalin Capsule

Produkt Beschreibung

1. Classification and Chemical Overview

Lyrica is the original innovator oral solid pharmaceutical brand containing Pregabalin (developed and commercialized by Pfizer). Chemically designated as $(3S)\text{-3-(aminomethyl)-5-methylhexanoic acid}$, pregabalin is a synthetic branched-chain aliphatic carboxylic acid belonging to the gabapentinoid chemical class. Structurally, it is an alkylated structural analogue of the principal inhibitory neurotransmitter $\gamma\text{-aminobutyric acid}$ (GABA), featuring an isobutyl substitution at the carbon-3 ($\beta$) position. It is synthesized and formulated exclusively as the biologically active $(S)\text{-enantiomer}$. Its empirical formula is $\text{C}_8\text{H}_{17}\text{NO}_2$, with a molecular weight of $159.23\text{ g/mol}$.

In the United Kingdom, Lyrica is presented as hard gelatin capsules across a comprehensive spectrum of standardized strength tiers, each differentiated by capsule shell color and debossed branding (imprinted with black ink indicating “Pfizer” on the cap and the code “PGN [strength]” on the body):

• 25mg: White body / white cap (debossed “PGN 25”)

• 50mg: White body / white cap with black band (debossed “PGN 50”)

• 75mg: White body / orange cap (debossed “PGN 75”)

• 100mg: Orange body / orange cap (debossed “PGN 100”)

• 150mg: White body / white cap (debossed “PGN 150”)

• 200mg: Light orange body / light orange cap (debossed “PGN 200”)

• 225mg: White body / light orange cap (debossed “PGN 225”)

• 300mg: White body / orange cap (debossed “PGN 300”)

Standard non-active pharmaceutical excipients within the capsule core include lactose monohydrate, pregelatinized maize starch, and talc. The capsule shells are composed of gelatin, titanium dioxide (E171), and iron oxide red/yellow (E172) for colored variants.

Within the United Kingdom regulatory framework:

• Medicinal Classification: Categorized as a Prescription Only Medicine (POM) governed by the Human Medicines Regulations 2012.

• Controlled Drug Rescheduling (2019): Following extensive clinical toxicology alerts, rising coroner death notifications, and formal advisory reports from the Advisory Council on the Misuse of Drugs (ACMD) regarding rising diversion and recreational misuse, pregabalin was officially reclassified in April 2019 as a Class C controlled substance under the Misuse of Drugs Act 1971 and placed into Schedule 3 (CD No Register POM) under the Misuse of Drugs Regulations 2001.

• Statutory Prescription Requirements: As a Schedule 3 Controlled Drug:

  • Prescriptions are legally valid for a maximum of 28 days from the date of signing.

  • Prescriptions must comply with strict statutory Controlled Drug requirements (the exact formulation, strength, dosing instructions, and total quantity written in both words and figures).

  • Repeat dispensing (batch prescribing) is prohibited.

  • It is legally exempt from statutory Safe Custody register-logging requirements in registered retail community pharmacies.

• NHS Formulary Positioning: Catalogued in the British National Formulary (BNF) and listed on the NHS Drug Tariff for licensed neuropathic, epileptic, and anxiety indications.

In community addiction landscapes and post-mortem toxicology, diverted pharmaceutical Lyrica or counterfeit pressed capsules (often dubbed “Buds”, “Pregabs”, or “Signature”) represent a substantial public health threat. Illicit capsules acquired via street markets or online platforms routinely exhibit severe dosage inconsistencies or carry active adulteration with illicit designer benzodiazepines (e.g., bromazolam) or synthetic nitazene opioids, significantly multiplying overdose lethality.

2. Mechanism of Action and Pharmacodynamics

Despite being a structural analogue of GABA, pregabalin displays no direct binding affinity for $GABA_A$, $GABA_B$, or benzodiazepine receptor sites. It does not metabolize into GABA, does not alter physiological GABA reuptake, and does not inhibit GABA transaminase:

• High-Affinity Binding to Voltage-Gated Calcium Channel $\alpha_2\delta$ Subunits:

  • Pregabalin exerts its clinical effects by binding with high stereospecific affinity to the auxiliary $\alpha_2\delta\text{-1}$ und $\alpha_2\delta\text{-2}$ protein subunits of presynaptic voltage-gated calcium channels (VGCCs) concentrated throughout the neocortex, amygdala, hippocampus, and the superficial dorsal horn of the spinal cord.

  • Its binding affinity ($K_d \approx 30\text{ to }40\text{ nM}$) is roughly six times greater than that of gabapentin, conferring its significantly higher clinical potency per milligram.

• Presynaptic Calcium Influx Blunting and Neurotransmitter Suppression:

  • In hyperexcitable or pathologically sensitized states (such as damaged sensory neurons in peripheral neuropathy or overactive fear networks in generalized anxiety), presynaptic VGCC density is markedly upregulated.

  • Occupancy of the $\alpha_2\delta$ subunit by pregabalin blunts depolarization-induced calcium ($Ca^{2+}$) influx through the presynaptic terminal.

  • Reduced intracellular calcium entry prevents the vesicular docking and exocytosis of primary excitatory neurotransmitters, notably L-glutamate, substance P, calcitonin gene-related peptide (CGRP), and noradrenaline.

• Normalization of Neuronal Hyperexcitability:

  • By dampening excessive excitatory transmission without completely abolishing basal synaptic firing, pregabalin produces targeted analgesia, anticonvulsant activity, and anxiolysis.

• Secondary Neurochemical Adaptations:

  • Sustained exposure impairs the forward trafficking and cell-surface membrane insertion of functional $\alpha_2\delta$ subunits from intracellular stores.

  • It produces downstream modulations of non-vesicular GABA transport density over prolonged maintenance.

• Receptor Non-Interactions: Pregabalin displays no direct affinity for human $\mu$-, $\kappa$-, or $\delta$-opioid receptors, serotonin receptors, dopamine receptors, or peripheral autonomic adrenoceptors.

3. Approved UK Clinical Indications and Therapeutic Scope

Lyrica holds licensed therapeutic indications within the British National Formulary (BNF) and National Institute for Health and Care Excellence (NICE) guidelines:

• Peripheral and Central Neuropathic Pain:

  • Indicated for the treatment of peripheral neuropathic pain (e.g., painful diabetic peripheral neuropathy, post-herpetic neuralgia) and central neuropathic pain (e.g., spinal cord injury, central post-stroke pain).

  • Evaluated within NICE Guideline CG173 (Neuropathic pain in adults), where pregabalin is positioned as a first-line pharmacological option alongside amitriptyline, duloxetine, and gabapentin.

  • Standard Dosing: Initiated at $150\text{ mg/day}$ in two or three divided doses (e.g., $75\text{ mg}$ BD or $50\text{ mg}$ TDS). Based on efficacy and tolerability, the dose may be increased to $300\text{ mg/day}$ after 3 to 7 days, and titrated to a maximum ceiling of $600\text{ mg/day}$ after an additional 7-day interval.

• Epilepsy (Adjunctive Therapy for Focal Seizures):

  • Indicated as adjunctive therapy in adults with focal seizures, with or without secondary generalization.

  • Positioned in NICE Guideline NG217 (Epilepsies). Dosing matches neuropathic schedules, titrating from $150\text{ mg/day}$ up to $600\text{ mg/day}$ in divided doses.

• Generalized Anxiety Disorder (GAD):

  • Indicated for the treatment of Generalized Anxiety Disorder in adults.

  • Evaluated within NICE Guideline CG113 (Anxiety disorders), where pregabalin is recommended for individuals refractory to, or intolerant of, first-line selective serotonin reuptake inhibitors (SSRIs) or serotonin-noradrenaline reuptake inhibitors (SNRIs). Initial dose: $150\text{ mg/day}$ divided into two or three doses, titrating incrementally up to $300\text{ to }600\text{ mg/day}$.

• Fibromyalgia (Off-Label UK Specialist Use):

  • Frequently prescribed off-label by rheumatologists and chronic pain specialists for central sensitization, widespread body aching, and associated sleep fragmentation ($150\text{ to }450\text{ mg/day}$).

In non-medical, illicit environments, Lyrica is misused for:

• Recreational Intoxication: Large oral doses ($300\text{ to }1,200+\text{ mg}$) produce an empathogenic, disinhibited, euphoric, and dissociative state (often described as a hybrid between alcohol intoxication and MDMA-like sensations).

• Opioid Withdrawal Self-Management: Ingested in supratherapeutic amounts by individuals with opioid use disorder to suppress the severe autonomic surges, restless legs, and muscle spasms of acute opioid withdrawal.

• Polydrug Potentiation: Co-administered with illicit opioids (heroin, methadone) or benzodiazepines to potentiate central sedative and euphoric effects.

4. Pharmacokinetic Profile and Metabolic Fate

The pharmacokinetic profile of Lyrica is characterized by rapid, complete intestinal absorption via active carrier-mediated transport, lack of hepatic metabolism, and exclusive renal elimination:

Absorption Kinetics (Linearity vs. Gabapentin)

• LAT1 Active Transport: Pregabalin is absorbed across the upper gastrointestinal mucosa via the system L-neutral amino acid transporter (LAT1 / SLC7A5).

• Predictable Linear Kinetics: Unlike gabapentin—which saturates LAT1 at therapeutic doses, causing bioavailability to fall sharply as dose increases—pregabalin displays linear, dose-proportional pharmacokinetics across its entire therapeutic range ($75\text{ to }600\text{ mg/day}$).

• Food Effects: Co-ingestion with food slows the absorption rate, decreasing $C_{max}$ by approximately $25\text{ to }30\%$ and delaying $T_{max}$ to approximately 2.5 hours, but does not alter the total area under the curve ($AUC$). Capsules can be taken with or without food.

Biotransformation and Renal Clearance

• Pregabalin undergoes negligible biotransformation in humans. Less than $2\%$ is metabolized, with only trace amounts of an inactive $N\text{-methylated}$ derivative detected in urine.

• It does not induce or inhibit CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4, avoiding cytochrome-mediated drug interactions.

• Systemic clearance is directly proportional to creatinine clearance ($\text{CrCl}$). In patients with renal impairment, the elimination half-life is substantially prolonged (exceeding $14\text{ to }20+\text{ hours}$ in moderate-to-severe CKD), requiring mandatory dose reductions.

• Pregabalin is readily dialyzable: a standard 4-hour hemodialysis session clears approximately $50\%$ of circulating drug from the blood.

5. Physiological Effects and Adverse Event Spectrum

Therapeutic administration stabilizes hyperexcitable neural pathways, mitigating neuropathic allodynia, suppressing focal seizure propagation, and blunting autonomic anxiety. However, widespread central $\alpha_2\delta$ modulation produces a broad adverse event spectrum:

• Central Nervous System and Cognitive Effects (Very Common, $\ge 1/10$):

  • Dizziness and Somnolence: The most common adverse effects, reported in over $25\text{ to }35\%$ of patients. Frequently dose-dependent, typically appearing during titration and often attenuating over several weeks of continuous therapy.

  • Cognitive Clouding: Attention deficits, psychomotor slowing, memory impairment, confusion, and dysarthria (slurred speech).

  • Cerebellar Ataxia and Incoordination: Motor unsteadiness, gait abnormalities, and tremors, significantly increasing the incidence of falls and fractures in elderly populations.

  • Euphoria: Reported in $1\text{ to }10\%$ of clinical trial participants, contributing to its intrinsic abuse liability.

• Ophthalmic Disturbances (Common, $1/100$ to $<1/10$):

  • Blurred vision, diplopia (double vision), and visual field changes resulting from central visual pathway modulation.

• Metabolic and Hemodynamic Effects (Common):

  • Peripheral Oedema: Dose-dependent fluid retention presenting as bilateral lower-extremity pitting oedema (incidence $5\text{ to }15\%$). Driven by microvascular tone alterations.

  • Weight Gain: Driven by increased appetite (hyperphagia) combined with fluid retention; long-term therapy produces clinically significant weight gain ($>7\%$ increase from baseline) in up to $15\%$ of patients.

  • Exacerbation of Heart Failure: Fluid retention can precipitate acute decompensation in patients with baseline NYHA Class III–IV congestive heart failure.

• Severe, Emergent and Life-Threatening Hazards:

  • Fatal Synergistic Respiratory Depression (MHRA Safety Alert): While isolated oral pregabalin overdose rarely produces fatal apnea in healthy individuals, co-administration with other central depressants (especially opioids, benzodiazepines, or alcohol) is lethal. Pregabalin blunts the hypoxic ventilatory response and magnifies opioid-induced medullary respiratory depression, substantially elevating fatal overdose rates in polysubstance users.

  • Rapid Physical Dependence and Severe Withdrawal Toxidrome: Abrupt cessation following as few as 2 to 4 weeks of continuous use triggers a severe withdrawal toxidrome:

    • Intense rebound insomnia, severe agitation, panic paroxysms, and profuse diaphoresis.

    • Gastrointestinal distress: nausea, vomiting, abdominal cramping, and severe diarrhea.

    • Neuromuscular hyperactivity: fine and coarse tremors, myoclonus, and autonomic instability (tachycardia, hypertension).

    • Withdrawal Seizures: Sudden discontinuation can precipitate status epilepticus, even in individuals taking Lyrica solely for pain or anxiety without any prior history of epilepsy.

  • Suicidal Ideation and Behavior (Class Warning): In common with other anticonvulsants, patients must be monitored for treatment-emergent depression, mood deterioration, or suicidal thoughts.

  • Severe Immunological Toxicities: Angioedema involving the tongue, glottis, larynx, and lips, risking acute upper airway obstruction; Stevens-Johnson syndrome (rare).

  • Rhabdomyolysis: Unexplained muscle pain, tenderness, or weakness accompanied by marked creatine kinase (CK) elevations.

6. Contraindications, Drug Interactions, and Clinical Precautions

Prescribing, titrating, and monitoring Lyrica requires strict adherence to renal dosing protocols, controlled drug surveillance, and respiratory risk stratification:

• Contraindications:

  • Hypersensitivity: Known hypersensitivity to pregabalin base or formulation excipients (including severe lactose intolerance or history of pregabalin-induced angioedema).

  • Severe Decompensated Heart Failure: Contraindicated or avoided in NYHA Class III–IV congestive heart failure unless clinical benefits clearly outweigh fluid retention risks.

  • Pregnancy and Teratogenicity (MHRA Drug Safety Update): Epidemiological data demonstrate that pregabalin use during the first trimester of pregnancy is associated with a slightly elevated risk of major congenital malformations (specifically structural malformations of the nervous system, eyes, face, and heart). Pregabalin must not be used during pregnancy unless clearly necessary, and women of childbearing potential must use effective contraception.

  • Breastfeeding: Pregabalin is excreted into human breast milk; breastfeeding is not recommended during therapy.

  • Paediatric Population: Not licensed for use in children and adolescents under 18 years of age due to lack of established safety and efficacy data.

• Drug Interactions:

  • Opioids (e.g., Morphine, Oxycodone, Methadone, Buprenorphine, Fentanyl): Highest-Tier Clinical Hazard. Co-administration exponentially magnifies the risk of fatal central respiratory arrest, profound sedation, coma, and severe constipation/paralytic ileus. Co-prescribing requires rigorous clinical documentation, minimum effective dosing, and close surveillance.

  • Benzodiazepines (e.g., Diazepam, Alprazolam, Clonazepam) and Alcohol: Additive central depression; marked synergistic impairment of psychomotor performance, cognitive processing, motor coordination, and respiratory drive.

  • Angiotensin-Converting Enzyme (ACE) Inhibitors (e.g., Ramipril, Lisinopril): Co-administration is associated with an increased incidence of peripheral oedema and angioedema.

  • Thiazolidinediones (e.g., Pioglitazone): Additive fluid retention and peripheral oedema, increasing the risk of precipitating heart failure.

• Clinical Precautions and Harm Minimisation:

  • Mandatory Renal Dosing Adjustments: Because clearance is directly linked to creatinine clearance, dosage must be individualized according to calculated renal function:

    • $\text{CrCl} \ge 60\text{ mL/min}$: Standard starting dose $150\text{ mg/day}$ (max $600\text{ mg/day}$ in 2 or 3 divided doses).

    • $\text{CrCl } 30\text{ to }<60\text{ mL/min}$: Starting dose $75\text{ mg/day}$ (max $300\text{ mg/day}$ in 2 or 3 divided doses).

    • $\text{CrCl } 15\text{ to }<30\text{ mL/min}$: Starting dose $25\text{ to }50\text{ mg/day}$ (max $150\text{ mg/day}$ in 1 or 2 divided doses).

    • $\text{CrCl } <15\text{ mL/min}$: Starting dose $25\text{ mg/day}$ (max $75\text{ mg/day}$ as a single daily dose).

    • Hemodialysis Patients: Administer an additional supplementary dose ($25\text{ to }100\text{ mg}$) immediately following each 4-hour hemodialysis treatment.

  • Structured Discontinuation Protocols: Lyrica must never be abruptly discontinued. In accordance with BNF recommendations, when terminating chronic therapy, the dose should be tapered gradually over a minimum of at least 1 week (or weeks-to-months in long-term high-dose dependent individuals, reducing by $50\text{ to }100\text{ mg}$ per week) to prevent withdrawal seizures, acute autonomic storms, and severe psychological rebound.

  • Driving and Operating Machinery: In accordance with the Road Traffic Act 1988, patients must be warned that pregabalin causes dizziness, visual disturbances, and somnolence. Patients must be explicitly advised not to drive or operate complex machinery until they are fully aware of how the medication affects them.

  • Acute Overdose Management (“Red Flags”):

    • Acute pregabalin overdose presents as somnolence, confusion, agitation, myoclonus, speech impairment, seizures, and respiratory depression (especially if co-ingested with opioids):

      • Airway and Ventilatory Support: Secure a patent airway, administer supplemental oxygen, and provide bag-valve-mask or mechanical ventilation if hypoventilation is present.

      • Seizure Control: Terminate acute seizures using intravenous benzodiazepines (e.g., IV diazepam $10\text{ mg}$ or lorazepam $2\text{ to }4\text{ mg}$).

      • Role of Naloxone: If co-ingestion with opioids is documented or suspected, administer intravenous naloxone ($400\text{ mcg}$ to $2\text{ mg}$) immediately to reverse opioid-induced respiratory depression (though naloxone will not reverse isolated pregabalin toxicity).

      • Extracorporeal Elimination: Because pregabalin is not bound to plasma proteins and has a modest volume of distribution, emergency hemodialysis is highly effective in clearing pregabalin from circulation and should be considered in severe, life-threatening overdoses complicated by acute renal failure.

Weitere Informationen